A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
Preclinical studies have indicated that T-cell immunoglobulin and ITIM domain (TIGIT) can substantially attenuate anti-tumoral immune responses. Although multiple clinical studies have evaluated the significance of TIGIT in patients with solid cancers, their results remain inconclusive. Thus, we con...
Main Authors: | Negar Hosseinkhani, Mahdi Abdoli Shadbad, Mohammad Asghari Jafarabadi, Noora Karim Ahangar, Zahra Asadzadeh, Seyede Momeneh Mohammadi, Parisa Lotfinejad, Nazila Alizadeh, Oronzo Brunetti, Rossella Fasano, Nicola Silvestris, Behzad Baradaran |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/19/10389 |
Similar Items
-
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
by: Anand Rotte, et al.
Published: (2021-09-01) -
Update in TIGIT Immune-Checkpoint Role in Cancer
by: Tiziana Annese, et al.
Published: (2022-05-01) -
Expression and Clinical Significance of TIGIT in Primary Breast Cancer
by: Tang L, et al.
Published: (2023-06-01) -
Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
by: Wenchao Li, et al.
Published: (2018-12-01) -
Peptide-based PET imaging agent of tumor TIGIT expression
by: Dinghu Weng, et al.
Published: (2023-05-01)